Cardiovascular Drugs and Therapy

, Volume 19, Issue 2, pp 119–124

Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk

  • Adriaan A. Voors
  • Pieter J. de Kam
  • Maarten P. van den Berg
  • Claudio Borghi
  • Judith S. Hochman
  • Dirk J. van Veldhuisen
  • Wiek H. van Gilst
Clinical Trials


Introduction: Ventricular remodeling starts very early after the onset of an acute myocardial infarction (AMI), and can be prevented by ACE-inhibitors. However, very limited data are available on the effect of acute (< 9 hours) treatment with angiotensin converting enzyme (ACE) inhibitors after an AMI on mortality, heart failure and re-infarction. The aim of the present study was to evaluate the effects of acute ACE-inhibitor treatment.

Methods: We performed a pooled analysis of three very similar randomized, placebo-controlled multi-center trials. In 845 thrombolysed patients with mainly first anterior MI, patients were randomised to acute ACE-inhibitor treatment (< 9 hours after MI) or placebo.

Results: After acute ACE-inhibitor treatment we observed similar 3-months mortality rates, and a significant reduction in the incidence of 3-months heart failure (26.1 vs. 19.3%; RR 0.67; 95% CI 0.45–1.0) as compared to placebo. In contrast, acute ACE-inhibitor treatment was associated with a significant 2.0 times increased 3-months re-infarction risk (7.0 vs. 3.6%; RR 2.0; 95% CI 1.1 to 3.8). Subgroup-analysis showed that patients with small infarct sizes treated with acute ACE-inhibitor (peak CPK < 1000 IU) had a 7.6 times higher re-infarction risk (95% CI 1.7 to 33) than patients with small infarctions treated with placebo.

Conclusions: Acute ACE-inhibitor treatment in thrombolysed patients with mainly first anterior AMI resulted in a reduction of heart failure and similar mortality, but an increase in re-infarction rates, especially in patients with small infarct sizes. These results warrant caution for the very early use of ACE-inhibitors in smaller infarctions, although this needs to be confirmed in a larger prospective randomised clinical trial.

Key Words

myocardial infarction mortality morbidity pooled-analysis reperfusion angiotensin-converting enzyme inhibitor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–677.Google Scholar
  2. 2.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670–1676.Google Scholar
  3. 3.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342(8875):821–828.Google Scholar
  4. 4.
    GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994;343(8906):1115–1122.Google Scholar
  5. 5.
    ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345(8951):669–685.Google Scholar
  6. 6.
    van Gilst WH, Kingma JH, Peels KH, Dambrink JH, St John SM. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol 1996;28(1):114–121.Google Scholar
  7. 7.
    Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosioni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J 1998;136(2):213–225.Google Scholar
  8. 8.
    de Kam PJ, Voors AA, van den Berg MP, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a pooled-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol 2000;36(7):2047–2053.Google Scholar
  9. 9.
    GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. GISSI-3-Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Am J Cardiol 1992;70(10):62C–69C.Google Scholar
  10. 10.
    ISIS Collaborative Group OU. ISIS-4: Randomised study of oral captopril in over 50 000 patients with suspected acute myocardial infarction. Circulation 1993;88:I-394–I-394.Google Scholar
  11. 11.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 Jan 22;355 (9200):253–9355(9200):253–259.Google Scholar
  12. 12.
    Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998;19(Suppl J):J52-5–J52–J55.Google Scholar
  13. 13.
    Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991;337(8746):872–876.Google Scholar
  14. 14.
    Vannan M, Taylor D, Esakoff D, Webb-Peploe M. Early enalapril therapy attenuates acute infarct expansion and late global ventricular dilatation after first myocardial infarction: 1 year follow-up. Circulation 1993;88:1395–1395.Google Scholar
  15. 15.
    French JK, Amos DJ, Williams BF, et al. Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow. J Am Coll Cardiol 1999;33(1):139–145.Google Scholar
  16. 16.
    White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317(14):850–855.Google Scholar
  17. 17.
    Pfeffer MA, Hennekens CH. When a question has an answer: Rationale for our early termination of the HEART Trial. Am J Cardiol 1995;75(16):1173–1175.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Adriaan A. Voors
    • 1
    • 5
  • Pieter J. de Kam
    • 1
  • Maarten P. van den Berg
    • 1
  • Claudio Borghi
    • 2
  • Judith S. Hochman
    • 3
  • Dirk J. van Veldhuisen
    • 1
  • Wiek H. van Gilst
    • 1
    • 4
  1. 1.Department of CardiologyUniversity Hospital GroningenThe Netherlands
  2. 2.Department of CardiologyUniversity of BolognaItaly
  3. 3.Department of CardiologySt. Luke’s-Roosevelt HospitalUSA
  4. 4.Department of Clinical PharmacologyUniversity of Groningenthe Netherlands
  5. 5.Department of CardiologyUniversity Hospital GroningenThe Netherlands

Personalised recommendations